New directions for drug discovery

Figures & data

Figure 1. Research budget (billion $) and total number of US drug registrations in 2003.

Figure 2. Reasons for stopping clinical development of 121 compounds in clinical trials carried out by seven British companies. PK, pharmacokinetics

Figure 3. Signaling genes in the human genome.

Figure 4. Screening of compound libraries: main pathway-dedicated platforms. GPC, G protein-coupled (Figure courtesy of Olivier Nosjean and Jean Boutin, Servier research).

Table I. What are the main factors influencing success in drug discovery processes, and how can research output be improved?

Figure 5. The impact of stress on neuroplasticity may be a novel target for drugs in psychiatry, as stress inhibits plasticity in hippocampal and prefrontal cortex circuits while increasing plasticity in the circuits dealing with emotion (amygdala, prefrontal cortex).¹⁰

SpeddingM.JayT.Costa e SilvaJ.PerretL.A pathophysiological paradigm for the therapy of psychiatric disease.Nature Drug Discovery.20054467476

 PubMed Web of Science ®Google Scholar